Hangping Zheng

Hangping Zheng

Auto-generated profile, based on publicly available information

Hangping Zheng

Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in eClinicalMedicine
Verified
Journal Article
Open access
HZHangping Zheng
Hangping Zheng
WSWanwan Sun
Wanwan Sun
QZQi Zhang
Qi Zhang
YZYuanpin Zhang
Yuanpin Zhang
LJLijin Ji
Lijin Ji
SZShuo Zhang
Shuo Zhang
Inflammation has been implicated in the pathogenesis of diabetic peripheral neuropathy (DPN) as suggested in various cross-sectional studies. However, more convincing prospective studies in diabetes patients are scarce. Therefore, we aimed to evaluate whether proinflammatory cytokines could predict the incidence of DPN through a prospective study with a five-year follow-up. We followed up 315 patients with diabetes who did not have DPN, recruited from five community health centers in Shanghai in 2014, for an average of 5.06 years. Based on the integrity of blood samples, 106 patients were selected to obtain the proinflammatory cytokines. Plasma markers of proinflammatory cytokines at baseline included interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), and intercellular adhesion molecule 1 (ICAM-1). Neuropathy was assessed by MSNI at baseline and during follow-up. Among the 106 chosen patients, 63 developed DPN after 5.06±1.14 years of follow-up. The baseline plasma levels of TNF-α, IL-6, and ICAM-1 were higher in the neuropathic group (p<0.05). In multivariate models, increased plasma levels of TNF-α (hazard ratio, HR: 8.74 [95% confidence interval, CI: 1.05–72.68]; p <0.05) and ICAM-1 (HR 23.74 [95% CI:1.47–383.81]; p<0.05) were both associated with incident DPN, after adjusting for known DPN risk factors. Increased plasma levels of proinflammatory factors, especially TNF-α and ICAM-1, predicted the incidence of DPN over 5 years in Chinese diabetes patients, but larger longitudinal studies are required for confirmation. National Natural Science Foundation of China, Shanghai Talent Development Fund Program, Shanghai Shenkang Hospital Developing Center Clinical Scientific and Technological Innovation Program, Shanghai Science and Technology Committee Program, Shanghai General Hospital Program of Chinese traditional and Western medicine combination and Shanghai Municipal Commission of Health and Family Planning Clinical Research Project.

1 May 2019 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
QLQingchun Li
Qingchun Li
YZYing Zhong
Ying Zhong
TZTiansong Zhang
Tiansong Zhang
RZRuiyun Zhang
Ruiyun Zhang
QZQi Zhang
Qi Zhang
QXQian Xiong
Qian Xiong

29 May 2018 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
NYNa Yi
Na Yi
SLSiying Liu
Siying Liu
HZHangping Zheng
Hangping Zheng
XQXiaona Qiao
Xiaona Qiao
BLBin Lu
Bin Lu
Objective: The 10 g Semmes–Weinstein monofilament evaluation (SWME) of 4 sites on each foot is recommended for distal symmetric polyneuropathy screening and diagnosis. A similar method has been proposed to diagnose ‘high-risk’ (for ulceration) feet, using 3 sites per foot. This study compared the effectiveness of SWME for testing 3, 4 and 10 sites per foot to identify patients with diabetic neuropathy. Methods: We included 3497 subjects in a SWME of 10 sites; records from the 10-site SWME were used for a SWME of 3 and 4 sites. Neuropathy symptom scores and neuropathy deficit scores were evaluated to identify patients with diabetic peripheral neuropathy. Results: The sensitivities of the 10 g SWME for 3, 4 and 10 sites were 17.8%, 19.0% and 22.4%, respectively. The Kappa coefficients for the SWME tests of 3, 4 and 10 sites were high (range: 0.78–0.93). Conclusions: There were no significant differences in the effectiveness of 3-, 4- and 10-site SWME testing for diabetic peripheral neuropathy screening. SWME testing of 3 sites on each foot may be sufficient to screen for diabetic neuropathy.

31 May 2020 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
ZHZheng Hangping
Zheng Hangping
HLHan Ling
Han Ling
JLJi Lijin
Ji Lijin
ZWZhao Wenting
Zhao Wenting
LXLiu Xiaoxia
Liu Xiaoxia
SZShuo Zhang
Shuo Zhang
Objective: To investigate the relationship between Interleukin-1beta (IL-1beta) and diabetic peripheral neuropathy (DPN) using animal models. Materials: The rat model of diabetic neuropathy was induced by intraperitoneal injection of a single dose of streptozotocin (STZ) at 65mg/kg. Diabetic rats were randomly divided into two groups (10 each), one treated with 0.9% saline (DMS group) and the other with interleukin-1 receptor antagonist (IL-1RA) at 50mg/kg (DMI group) twice a day for 5 weeks. Ten normal rats matched for weight, age and sex served as normal controls (Con group) and were treated with saline. Morphologic studies of sciatic nerves were achieved using light and transmission electron microscopy. Results: Transmission electron microscopy of the sciatic nerve showed the ultrastructure of myelin and the axon in the IL-1RA group was highly protected compared to diabetic controls. Conclusions: High levels of circulating IL-1beta may be associated with the risk of DPN and anti-IL-1 treatment may provide a potential strategy for the prevention of diabetic neuropathy.

23 December 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
QCQiaoli Cui
Qiaoli Cui
ZZZhenming Zhang
Zhenming Zhang
LQLang Qin
Lang Qin
ZTZhaolin Teng
Zhaolin Teng
ZWZhihong Wang
Zhihong Wang
ZXZhu Xiaoming
Zhu Xiaoming
Aims/Introduction: Diabetic foot ulcer (DFU) is a prevalent complication of diabetes characterized by heightened inflammation and impaired wound‐healing processes. Interleukin‐37 (IL‐37) is a natural suppressor of innate inflammation. Here, we aim to investigate the potential of IL‐37 in enhancing the healing process of diabetic wounds.Materials and Methods: The skin samples of DFU and non‐diabetic patients during foot and ankle orthopedic surgery were collected. The IL‐37 transgenic mice (IL‐37Tg) were created using CRISPR/Cas‐mediated genome engineering. Mice were administered streptozotocin (STZ, 150 mg/kg) to induce a diabetic model. After 4 weeks, an equidistant full‐thickness excisional wound measuring 8 mm was created on the central back of each mouse and allowed to heal naturally. Body weight and blood glucose levels were measured weekly. The wound area was measured, and skin samples were collected on Day 10 for further Quantitative polymerase chain reaction (qPCR) and WB detection and RNA sequencing analysis.Results: The proinflammation cytokines such as TNF‐α and IL‐1β and the MAPK signaling pathway were significantly increased in the wound margin of DFU patients. Compared with diabetic mice, diabetic IL‐37Tg mice showed a significantly accelerated healing process. The enriched signaling pathways in RNA sequencing included cytokine–cytokine receptor interaction, TNF signaling pathway, and NOD‐like receptor signaling pathway. Through QPCR and WB detection, we found that IL‐37 could inhibit the activated MAPK and NOD‐like signaling pathway, reducing TNF‐α, IL‐1β, and NLRP3 expression in the diabetic wound.Conclusions: IL‐37 promotes skin wound healing in diabetic mice, providing a new possible target for treating diabetic wounds.

1 January 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
HZHangping Zheng
Hangping Zheng
WSWanwan Sun
Wanwan Sun
QZQi Zhang
Qi Zhang
YZYuanpin Zhang
Yuanpin Zhang
LJLijin Ji
Lijin Ji
SZShuo Zhang
Shuo Zhang
Aims: Inflammation has been implicated in the pathogenesis of diabetic peripheral neuropathy (DPN) as suggested in various cross-sectional studies. However, more convincing prospective studies in diabetes patients are scarce. Therefore, we aimed to evaluate whether proinflammatory cytokines could predict the incidence of DPN through a prospective study with a five-year follow-up.Methods: We followed up 315 patients with diabetes who did not have DPN, recruited from five community health centers in Shanghai in 2014, for an average of 5.06 years. Based on the integrity of blood samples, 106 patients were selected to obtain the proinflammatory cytokines. Plasma markers of proinflammatory cytokines at baseline included interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), and intercellular adhesion molecule 1 (ICAM-1). Neuropathy was assessed by MSNI at baseline and during follow-up.Results: Among the 106 randomly chosen patients, 63 developed DPN after 5.06±1.14 years of follow-up. The baseline plasma levels of TNF-α, IL-6, and ICAM-1 were higher in the neuropathic group (P<0.05). In multivariate models, increased plasma levels of TNF-α (hazard ratio, HR: 8.74 [95% confidence interval, CI: 1.05-72.68]; p <0.05) and ICAM-1 (HR 23.74 [95% CI 1.47-383.81]; p <0.05) were both associated with incident DPN, after adjusting for known DPN risk factors.Conclusions: Increased plasma levels of proinflammatory factors, especially TNF-α and ICAM-1, predicted the incidence of DPN over 5 years in Chinese diabetes patients, but larger longitudinal studies are required for confirmation.Funding Statement: The present study was supported by grants from the National Natural Science Foundation of China (81770807, to B Lu and 81800692, to LJ Ji), Shanghai Talent Development Fund Program (2018054, to B Lu), Shanghai Shenkang Hospital Developing Center Clinical Scientific and Technological Innovation Program (SHDC12016210, to B Lu), Shanghai Science and Technology Committee Program (17411961500, to S Zhang), Shanghai General Hospital Program of Chinese traditional and Western medicine combination (ZY(2018-2020)-FWTX-1002, to YM Li) and Shanghai Municipal Commission of Health and Family Planning Clinical Research Project (20184Y0318, to LJ Ji). Declaration of Interests: The authors declare that there is no conflict of interest.Ethics Approval Statement: The study was approved by the Human Investigation Ethics Committee of Huashan Hospital.